Eye safety has followed these drugs since the first reports of optic nerve damage, examined here in the optic nerve evidence by indication. A retrospective cohort took a different question to a multinational database: among people already taking one of these drugs, does it matter which one [1].
Adults aged 60 and over with type 2 diabetes who were newly prescribed tirzepatide or another GLP-1 drug between 2022 and 2024 were matched one to one on age, sex, race, smoking history, HbA1c, BMI, prior glucose-lowering medication, corticosteroid use and comorbidities. Anyone with existing glaucoma, prior glaucoma medication, or who used both drug types during follow-up was excluded. Across 51,540 participants followed for two years, incident primary open-angle glaucoma came in at a hazard ratio of 0.65 (95% CI 0.44–0.96) on tirzepatide, and the finding survived several sensitivity analyses including an intention-to-treat design.
The interval is worth reading rather than rounding. An upper bound of 0.96 clears 1 by four hundredths, which means the result is real by the usual convention and fragile under any reasonable amount of unmeasured confounding. Two years is also a short window for a disease that develops over decades, and a diagnosis of open-angle glaucoma depends on somebody having an eye examination at all, which is the same detection problem that shapes the retinopathy evidence.
What would make this more than a curiosity is a mechanism, and the study does not supply one. Intraocular pressure, blood sugar variability and weight change are all plausible routes and none was measured. Until an untreated comparison exists, the practical use of this finding is narrow: it is one more entry in the growing list of small differences between two drugs that are usually discussed as interchangeable, alongside the carpal tunnel comparison and the network comparison.